Micromet Inc (MITI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI)

MITI 0.0446

+6.4%

Dec 9 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dr.praveen who wrote (36)	8/5/2006 5:47:22 PM
From: tuck	Read Replies (1) of 196

The Bites have quite a short serum half-life at two hours. What is meant in the PR by a "continuous infusion of MT103 over a 4- to 8-week period at escalating dose levels?" Does this mean the patients were rigged with a pump? If so, rather invasive; not exactly as patient friendly as a tablet, S.C. injection or even an I.V. from time to time. Wouldn't this make them a hard sell despite efficacy? Also, comparing objective responses against Rituxan in NHL, the two seem roughly even, though the MT-103 studies are too small to be able to draw reliable comparisons. If I've got this dosing issue right, it seems as though Rituxan has the advantage, except perhaps -- and this IS important -- in terms of side effect profile. Reformulation might be needed for success? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next